

---

# **Preliminary Results of MURIA Group Antibiotic Utilization Studies Using Point Prevalence Survey In Botswana**

Bene D Anand Paramadhas, Joyce Kgatlwane, Celda Tiroyakgosi, Matshediso Matome, Amos Masseur, Jaran Eriksen, Lars L Gustafsson, Arno Muller, Brian Godman




# BACKGROUND

- Bacterial resistance to antibiotics is a recognized emerging public health problem.
- A burden for public health systems.
- Threatens the progress in achieved health gains of countries.
- Inappropriate and indiscriminate use and disposal of antibiotics across human and veterinary health sectors and by industry are the main factors that promote evolution of bacterial resistance.
- The extent and appropriateness of antibiotic use in Botswana remains unknown.
- Countries are expected to develop a national action plan as per recent WHA resolution

## 2. AMR A GLOBAL PUBLIC HEALTH THREAT


### UK's Independent Review by Lord Jim O'Neill

- DRIs cause 700,000 deaths worldwide each year
- At this rate by 2050 globally there would be 10 million deaths a year annually.
- The report provides a roadmap how the situation can be controlled through national and international efforts.



## 2. AMR A GLOBAL PUBLIC HEALTH THREAT!

Deaths attributable to AMR every year by 2050




Mortality per 10,000 population




Source: Review on Antimicrobial Resistance

# RESISTANCE PATTERNS AT NYANGABGWE HOSPITAL




# RESISTANCE PATTERNS AT NYANGABGWE HOSPITAL

## *Enterococcus spp.*




# RESISTANCE PATTERNS AT NYANGABGWE HOSPITAL

## Trend of Antimicrobial Resistance of Escherichia coli in pus




# RESISTANCE PATTERNS AT NYANGABGWE HOSPITAL

## Trend of Antimicrobial Resistant in *Klebsiella pneumoniae* in pus




# RESISTANCE PATTERNS AT NYANGABGWE HOSPITAL

## Resistance of Cefotaxime & Amoxicillin Clavulanic acid (% Isolates)



# RESISTANCE PATTERNS AT NYANGABGWE HOSPITAL

## ESBL Trend in Gram-negative bacilli



# OBJECTIVES

- To describe the extent of antibiotic use in hospitalized patients; and
- Assess the structural capacity for promotion of appropriate antibiotic use in hospitals

# METHODOLOGY

- **Study design** is quantitative observational descriptive.
- **Study method** involved a structured point prevalence survey to describe the extent and appropriateness of antibiotic use and to assess the institutional capacity for promotion of appropriate antibiotic use.
- **Study variables** had categorical and discrete at hospital, ward and patient levels.
- **Study settings** included 9 public and 1 private for profit hospitals representing all geographical regions of the country offering primary, secondary, tertiary and specialized care services.
- **Sampling frame** involved medical records of all inpatients that remained admitted overnight on the date of survey in the above 10 hospitals
- **Study sample** involved medical records of all patients or an authorized person who provided a voluntary verbal informed consent.

# METHODOLOGY

- **Inclusion Criteria**

Medical records of all inpatients that remained admitted overnight on the date of survey

- **Exclusion Criteria**

Medical records of:

- Patients or authorized persons who do not grant consent
- Accident & emergency outpatients
- Consulted outpatients
- Patients kept in observation after chemotherapy or minor procedures who did not stay overnight
- Discharged patients lodging in ward due to lack of transport to their facility or homes
- Patients in labour ward
- Psychiatric in-patients and
- Inpatients who are exclusively on TB treatment.

# METHODOLOGY

## Definitions

- **Extent of antibiotic use** is the description of the pattern of antibiotic prescriptions made in reference to the various settings, patient and disease characteristics.
- **Appropriateness of antibiotic use** is the assessment of antibiotic prescriptions against the current national antimicrobial guidelines for adherence.
- **Structural capacity** means the ability of the hospitals to provide for the needs to promote appropriate antimicrobial use for achieving appropriate outcomes.
- **Point Prevalence** measures the prevalence of antibiotic use during the current hospitalization episode (not what is prescribed on the date of survey)

# METHODOLOGY

## Ethical Considerations

- **Ethical consent granted** by the Health Research and Development Division (13/18/1 X(560) and by all hospital research and ethics committees or managements.
- **Hospital employees who were trained** by MURIA & University of Botswana on “Principles in Research Ethics” and on the “Structured Data Collection Tool” or by one of the co-researchers.
- **Patients or authorized persons were explained** about the study and assurance of confidentiality through anonymizing collected data, clarified their doubts to receive verbal voluntary informed consent.
- **All collected data were de-identified** by data collectors at their hospitals to anonymize data before emailed to investigators.
- **Investigators assured of results** to be shared with their respective hospitals.

# METHODOLOGY

## Data Collection

- Data collected through **trained hospital employees or volunteering staff** oriented to the Principles in Research Ethics” and on the “Structured Data Collection Tool” or by one of the co-researchers.
- **Communication support provided** through telephonic and email communications to clarify any doubts.
- **Data collected in hard copies** of the tool and **captured on the standardized Excel template** with drop-down menus.
- **Data collected in 30 working days** in 10 hospitals (3<sup>rd</sup> May to 14<sup>th</sup> June 2017)
- Data collection **took one day for Primary and Specialized hospitals** with one and five data collectors respectively; **3 to 5 days in District hospitals** with 1 to 2 data collectors and **10 days in referral hospital** with 2 data collectors.

# METHODOLOGY

## Data Validation

- Data validation was done prior to data analysis through **data exploration** to identify typographical errors, extreme values, incomplete, missing and incoherent responses to eliminate errors and prepare for the analysis. All concerned entries were verified with data collectors for suitable amendments.

## Data Analysis

- Data analysed using MS-Excel-2013 and presented as **frequencies and percentages** with mean and standard deviation or median and interquartile range.



# **RESULTS AND DISCUSSIONS**



# STUDY SITES

| <b>Level of Healthcare</b>                        | <b>Total</b> | <b>Facilities</b>   |
|---|--------------|---|
| <b>Public Primary Hospitals</b>                   | <b>4</b>     | <b>Bobonong Hospital, Gweta Hospital, Lethlakane Hospital, Goodhope Hospital.</b>   |
| <b>Public District Hospitals</b>                  | <b>4</b>     | <b>Lethsolathebe-II Memorial Hospital Maun, DRM Hospital Mochudi, Mahalapye Hospital , Scottish Memorial Hospital Molepolole.</b> |
| <b>Public Referral Hospitals</b>                  | <b>1</b>     | <b>Nyangabgwe Referral Hospital, Francistown</b>  |
| <b>Private for Profit - Specialized Hospitals</b> | <b>1</b>     | <b>Lenmed-Bokamoso Private Hospital, Gaborone.</b>  |
| <b>Total no. of Health Facilities</b>             | <b>10</b>    |   |


## INFORMED CONSENT AT HOSPITAL LEVEL

| <b>Health Facility</b> | <b>Bed Capacity</b> | <b>Admissions</b> | <b>Consented (Population)</b> | <b>% Consented</b> |
|------------------------|---------------------|-------------------|-------------------------------|--------------------|
| Primary Hospitals      | 20 - 50             | 69                | 67                            | 97,10              |
| District Hospitals     | 100 - 150           | 330               | 280                           | <b>84,85</b>       |
| Referral Hospital      | 572                 | 311               | 307                           | 98,71              |
| Specialized Hospital   | <100                | 63                | 57                            | 90,48              |
| Total                  |                     | <b>773</b>        | <b>711</b>                    | <b>92,37</b>       |

## INFORMED CONSENT AT WARD LEVEL

| <b>Ward Admissions &amp; Consent (N=773)</b> | <b>Admissions</b> | <b>Consented</b> | <b>% Consented</b> |
|--|-------------------|------------------|--------------------|
| Paediatric Intensive Care Unit (PICU)        | 6                 | 6                | 100                |
| Obstetrics & Gynaecology (OBGY)              | 209               | 199              | 95.22              |
| Adult Medical Ward (AMW)                     | 207               | 192              | 92.75              |
| Adult Surgical Ward (ASW)                    | 177               | 164              | 92.66              |
| Paediatric Surgical Ward (PSW)               | 34                | 31               | 91.18              |
| Adult Intensive Care Unit (AICU)             | 19                | 17               | 89.47              |
| Paediatric Medical Ward (PMW)                | 68                | 59               | 86.76              |
| Neonatal Intensive Care Unit (NICU)          | 53                | 43               | 81.13              |

## GENDER DISTRIBUTION (N=711)




■ Males ■ Females

## AGE DISTRIBUTION (N=711)

| Age Group        | Total      | Age (Mean)   | Standard Deviation | Median    | IQR       |
|------------------|------------|--------------|--------------------|-----------|-----------|
| Adult (Years)    | <b>627</b> | <b>38.79</b> | <b>22.28</b>       | <b>34</b> | <b>28</b> |
| Children (Years) | <b>21</b>  | <b>10.48</b> | <b>1.29</b>        | <b>10</b> | <b>3</b>  |
| Infants (Months) | <b>22</b>  | <b>3.95</b>  | <b>2.26</b>        | <b>4</b>  | <b>4</b>  |
| Neonates (Days)  | <b>41</b>  | <b>4.83</b>  | <b>6.95</b>        | <b>1</b>  | <b>5</b>  |

# EMPLOYMENT STATUS (N=512)

## Employment Status (%)



Employment Status was unknown for 199 admitted patients

# RISK FACTORS FOR POTENTIAL ANTIBIOTIC USE

## (PREVIOUS HOSPITALIZATIONS AND DISEASE CONDITIONS)

| Age Group          | Admissions    | Trans-In     | Prev-Hosp    | Malaria     | Malnourished | TB Positive  |
|--------------------|---------------|--------------|--------------|-------------|--------------|--------------|
| 0-29 days          | 41            | 29           | 5            | 0           | 1            | 0            |
| 1 to 11 months     | 23            | 7            | 0            | 0           | 2            | 1            |
| 1 to 5 years       | 45            | 15           | 6            | 0           | 7            | 0            |
| 6 to 10 years      | 22            | 13           | 7            | 0           | 1            | 3            |
| 11 to 15 years     | 18            | 9            | 0            | 0           | 1            | 0            |
| 16 to 20 years     | 39            | 14           | 1            | 0           | 2            | 2            |
| 21 to 25 years     | 84            | 24           | 5            | 0           | 0            | 2            |
| 26 to 30 years     | 70            | 30           | 5            | 0           | 0            | 3            |
| 31 to 35 years     | 76            | 31           | 9            | 0           | 3            | 2            |
| 36 to 40 years     | 55            | 26           | 5            | 0           | 5            | 9            |
| 41 to 45 years     | 39            | 15           | 6            | 0           | 0            | 1            |
| 46 to 50 years     | 35            | 12           | 5            | 0           | 0            | 2            |
| 51 to 55 years     | 28            | 13           | 6            | 1           | 2            | 1            |
| 56 to 60 years     | 25            | 8            | 2            | 0           | 0            | 1            |
| 61 to 65 years     | 18            | 11           | 1            | 0           | 0            | 0            |
| 66 and above       | 93            | 42           | 15           | 2           | 6            | 5            |
| <b>Total Cases</b> | <b>711</b>    | <b>299</b>   | <b>78</b>    | <b>3</b>    | <b>30</b>    | <b>32</b>    |
| <b>Unknown</b>     |               | <b>14</b>    | <b>97</b>    | <b>593</b>  | <b>112</b>   | <b>585</b>   |
| <b>N</b>           | <b>711</b>    | <b>697</b>   | <b>614</b>   | <b>118</b>  | <b>599</b>   | <b>126</b>   |
| <b>%</b>           | <b>100.00</b> | <b>42.90</b> | <b>12.70</b> | <b>2.54</b> | <b>5.01</b>  | <b>25.40</b> |

# RISK FACTORS FOR POTENTIAL ANTIBIOTIC USE (CATHETER USE)

| Age Group      | Admissions | None         | Peripheral   | Urinary     | Haemodialysis | Central     | Other       | Peritoneal |
|----------------|------------|--------------|--------------|-------------|---------------|-------------|-------------|------------|
| 0-29 days      | 41         | 9            | 32           | 0           | 0             | 0           | 0           | 0          |
| 1 to 11 months | 23         | 8            | 15           | 0           | 0             | 0           | 0           | 0          |
| 1 to 5 years   | 45         | 26           | 19           | 0           | 0             | 0           | 0           | 0          |
| 6 to 10 years  | 22         | 12           | 10           | 2           | 0             | 0           | 0           | 0          |
| 11 to 15 years | 18         | 10           | 8            | 1           | 0             | 1           | 0           | 0          |
| 16 to 20 years | 39         | 20           | 17           | 2           | 0             | 0           | 2           | 0          |
| 21 to 25 years | 84         | 37           | 46           | 4           | 0             | 0           | 0           | 0          |
| 26 to 30 years | 70         | 27           | 42           | 6           | 0             | 1           | 1           | 0          |
| 31 to 35 years | 76         | 28           | 46           | 6           | 0             | 0           | 1           | 0          |
| 36 to 40 years | 55         | 24           | 31           | 5           | 0             | 1           | 1           | 0          |
| 41 to 45 years | 39         | 18           | 20           | 4           | 1             | 0           | 0           | 0          |
| 46 to 50 years | 35         | 18           | 14           | 3           | 3             | 3           | 1           | 0          |
| 51 to 55 years | 28         | 12           | 14           | 3           | 0             | 0           | 1           | 0          |
| 56 to 60 years | 25         | 12           | 12           | 3           | 0             | 1           | 0           | 0          |
| 61 to 65 years | 18         | 9            | 7            | 3           | 3             | 1           | 0           | 0          |
| 66 and above   | 93         | 44           | 44           | 11          | 3             | 1           | 2           | 0          |
| <b>Total</b>   | <b>711</b> | <b>314</b>   | <b>377</b>   | <b>53</b>   | <b>10</b>     | <b>9</b>    | <b>9</b>    | <b>0</b>   |
| <b>%</b>       | <b>100</b> | <b>44.16</b> | <b>53.02</b> | <b>7.45</b> | <b>1.41</b>   | <b>1.27</b> | <b>1.27</b> | <b>0</b>   |

# RISK FACTORS FOR POTENTIAL ANTIBIOTIC USE (INTUBATION)

| Age Group      | Admissions | None         | Nasogastric | Endotracheal | Suction     | Tracheostomy | Gastroduodenal |
|----------------|------------|--------------|-------------|--------------|-------------|--------------|----------------|
| 0-29 days      | 41         | 14           | 27          | 1            | 1           | 0            | 0              |
| 1 to 11 months | 23         | 19           | 4           | 0            | 0           | 0            | 0              |
| 1 to 5 years   | 45         | 43           | 1           | 1            | 1           | 0            | 0              |
| 6 to 10 years  | 22         | 20           | 1           | 2            | 2           | 0            | 0              |
| 11 to 15 years | 18         | 16           | 1           | 2            | 2           | 1            | 0              |
| 16 to 20 years | 39         | 38           | 1           | 0            | 0           | 0            | 0              |
| 21 to 25 years | 84         | 80           | 2           | 1            | 1           | 0            | 0              |
| 26 to 30 years | 70         | 66           | 1           | 4            | 4           | 0            | 0              |
| 31 to 35 years | 76         | 71           | 3           | 3            | 3           | 0            | 0              |
| 36 to 40 years | 55         | 51           | 1           | 2            | 2           | 0            | 0              |
| 41 to 45 years | 39         | 38           | 1           | 1            | 1           | 0            | 0              |
| 46 to 50 years | 35         | 31           | 1           | 4            | 4           | 1            | 0              |
| 51 to 55 years | 28         | 28           | 0           | 0            | 0           | 0            | 0              |
| 56 to 60 years | 25         | 23           | 1           | 2            | 2           | 0            | 0              |
| 61 to 65 years | 18         | 17           | 0           | 1            | 1           | 0            | 0              |
| 66 and above   | 93         | 86           | 4           | 4            | 4           | 0            | 0              |
| <b>Total</b>   | <b>711</b> | <b>641</b>   | <b>49</b>   | <b>28</b>    | <b>28</b>   | <b>2</b>     | <b>0</b>       |
| <b>%</b>       | <b>100</b> | <b>90.15</b> | <b>6.89</b> | <b>3.94</b>  | <b>3.94</b> | <b>0.28</b>  | <b>0</b>       |

# RISK FACTORS FOR POTENTIAL ANTIBIOTIC USE

## (TYPE OF INFECTIONS)

| Age Group      | Admissions | Community Acquired Infection | % CAI        | Hospital Acquired Infection | % HAI        | Home based Care Infection | % HBCI      | Non-Infectious Conditions | % NIC        |
|----------------|------------|------------------------------|--------------|-----------------------------|--------------|---------------------------|-------------|---------------------------|--------------|
| 0-29 days      | 41         | 4                            | 9.76         | 24                          | <b>58.54</b> | 0                         | 0.00        | 13                        | 31.71        |
| 1 to 11 months | 23         | 19                           | 82.61        | 3                           | <b>13.04</b> | 0                         | 0.00        | 1                         | 4.35         |
| 1 to 5 years   | 45         | 33                           | 73.33        | 4                           | <b>8.89</b>  | 0                         | 0.00        | 8                         | 17.78        |
| 6 to 10 years  | 22         | 16                           | 72.73        | 0                           | 0.00         | 0                         | 0.00        | 6                         | 27.27        |
| 11 to 15 years | 18         | 10                           | 55.56        | 0                           | 0.00         | 0                         | 0.00        | 8                         | 44.44        |
| 16 to 20 years | 39         | 25                           | 64.10        | 2                           | 5.13         | 0                         | 0.00        | 12                        | 30.77        |
| 21 to 25 years | 84         | 60                           | 71.43        | 3                           | 3.57         | 0                         | 0.00        | 21                        | 25.00        |
| 26 to 30 years | 70         | 49                           | 70.00        | 2                           | 2.86         | 0                         | 0.00        | 19                        | 27.14        |
| 31 to 35 years | 76         | 54                           | 71.05        | 4                           | 5.26         | 0                         | 0.00        | 18                        | 23.68        |
| 36 to 40 years | 55         | 33                           | 60.00        | 2                           | 3.64         | 0                         | 0.00        | 20                        | 36.36        |
| 41 to 45 years | 39         | 23                           | 58.97        | 1                           | 2.56         | 0                         | 0.00        | 15                        | 38.46        |
| 46 to 50 years | 35         | 24                           | 68.57        | 1                           | 2.86         | 0                         | 0.00        | 10                        | 28.57        |
| 51 to 55 years | 28         | 15                           | 53.57        | 0                           | 0.00         | 0                         | 0.00        | 13                        | 46.43        |
| 56 to 60 years | 25         | 15                           | 60.00        | 0                           | 0.00         | 0                         | 0.00        | 10                        | 40.00        |
| 61 to 65 years | 18         | 8                            | 44.44        | 3                           | <b>16.67</b> | 1                         | <b>5.56</b> | 6                         | 33.33        |
| 66 and above   | 93         | 51                           | 54.84        | 11                          | <b>11.83</b> | 2                         | <b>2.15</b> | 29                        | 31.18        |
| <b>Total</b>   | <b>711</b> | <b>439</b>                   | <b>61.74</b> | <b>60</b>                   | <b>8.44</b>  | <b>3</b>                  | <b>0.42</b> | <b>209</b>                | <b>29.40</b> |

**Nearly 70% of the hospitalizations were for treatment of Infectious Diseases with a high proportion of HAIs occurring among children and elderly patients**


## RISK FACTORS FOR POTENTIAL ANTIBIOTIC USE (HIV & HAART STATUS)

|       | Admissions | Tested | Positive     | Negative | On HAART     |
|-------|------------|--------|--------------|----------|--------------|
| Total | 711        | 462    | 185          | 277      | 158          |
| %     | 100        | 64.97  | <b>40.04</b> | 59.95    | <b>85.40</b> |

**HIV related opportunistic infections increase the demand for prescription of antibiotics**


# RISK FACTORS FOR POTENTIAL ANTIBIOTIC USE

## PREVIOUS ANTIBIOTIC EXPOSURE (N=134)



# RISK FACTORS FOR POTENTIAL ANTIBIOTIC USE

## DURATION OF PRE-HOSPITALIZATION ANTIBIOTIC EXPOSURE






# **ADMISSION DIAGNOSIS USING ECDC CODES**



| Age Group | Admissions | Non Inf. NA | OBGY  | PNEU | SST  | GI   | CNS  | CSEP | BRON | BJ   | ENT  | CYS  | CVS  | FN   | PYE  | UND  | EYE  | GUM  | IA   | SIRS | ASB  | BAC  |
|-----------|------------|-------------|-------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| 0-29D     | 41         | 28          | 0     | 1    | 0    | 1    | 0    | 12   | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| 1-11M     | 23         | 3           | 0     | 12   | 1    | 2    | 0    | 2    | 3    | 0    | 2    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| 1-5Y      | 45         | 22          | 0     | 8    | 4    | 3    | 1    | 1    | 5    | 0    | 1    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| 6-10Y     | 22         | 9           | 0     | 2    | 3    | 0    | 2    | 0    | 1    | 3    | 0    | 0    | 1    | 0    | 0    | 0    | 0    | 0    | 1    | 0    | 0    | 0    |
| 11-15Y    | 18         | 14          | 1     | 1    | 2    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| 16-20Y    | 39         | 22          | 8     | 1    | 2    | 1    | 2    | 0    | 0    | 0    | 1    | 0    | 0    | 0    | 0    | 1    | 0    | 0    | 0    | 1    | 0    | 0    |
| 21-25Y    | 84         | 49          | 23    | 2    | 7    | 1    | 0    | 0    | 1    | 0    | 0    | 0    | 0    | 0    | 0    | 1    | 0    | 0    | 0    | 0    | 0    | 0    |
| 26-30Y    | 70         | 36          | 21    | 2    | 2    | 0    | 4    | 0    | 0    | 2    | 0    | 0    | 1    | 0    | 0    | 2    | 0    | 0    | 0    | 0    | 0    | 0    |
| 31-35Y    | 76         | 31          | 24    | 9    | 7    | 1    | 1    | 1    | 0    | 1    | 0    | 0    | 0    | 1    | 0    | 0    | 1    | 0    | 0    | 0    | 0    | 0    |
| 36-40Y    | 55         | 32          | 8     | 4    | 2    | 2    | 2    | 1    | 1    | 0    | 3    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| 41-45Y    | 39         | 18          | 6     | 3    | 4    | 5    | 2    | 0    | 0    | 1    | 0    | 0    | 0    | 1    | 2    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| 46-50Y    | 35         | 17          | 2     | 3    | 3    | 2    | 2    | 0    | 1    | 0    | 1    | 2    | 1    | 1    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| 51-55Y    | 28         | 14          | 0     | 2    | 2    | 2    | 1    | 0    | 0    | 1    | 0    | 0    | 1    | 2    | 2    | 0    | 1    | 0    | 0    | 0    | 0    | 0    |
| 56-60Y    | 25         | 17          | 1     | 1    | 4    | 1    | 0    | 0    | 0    | 0    | 1    | 0    | 1    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| 61-65Y    | 18         | 11          | 0     | 0    | 3    | 0    | 1    | 1    | 0    | 1    | 0    | 0    | 0    | 0    | 1    | 0    | 0    | 0    | 0    | 0    | 0    | 0    |
| >66Y      | 93         | 49          | 0     | 11   | 8    | 4    | 2    | 1    | 4    | 1    | 1    | 6    | 2    | 2    | 2    | 1    | 0    | 1    | 0    | 0    | 0    | 0    |
| Total     | 711        | 372         | 94    | 62   | 54   | 25   | 20   | 19   | 16   | 10   | 10   | 8    | 7    | 7    | 7    | 5    | 2    | 1    | 1    | 1    | 0    | 0    |
| %         | 100.00     | 52.32*      | 13.22 | 8.72 | 7.59 | 3.52 | 2.81 | 2.67 | 2.25 | 1.41 | 1.41 | 1.13 | 0.98 | 0.98 | 0.98 | 0.70 | 0.28 | 0.14 | 0.14 | 0.14 | 0.00 | 0.00 |

**\*22.92% of community acquired infections were diagnosed after admission.**

# MISSED ANTIBIOTIC DOSES



## ANTIBIOTIC PRESCRIBING RATIO & PATTERN

|                                       | Primary | District | Tertiary    | Specialty   |
|---------------------------------------|---------|----------|-------------|-------------|
| No. of patients requiring antibiotics | 67      | 280      | 307         | 57          |
| No. of antibiotics prescribed         | 77      | 283      | 541         | 81          |
| Antibiotic prescribing ratio          | 1.15    | 1.01     | <b>1.76</b> | <b>1.42</b> |

| ATC Code | Antibiotic                      | Prescriptions | Specialist | Tertiary   | District   | Primary   |
|----------|---------------------------------|---------------|------------|------------|------------|-----------|
| J01DD01  | <b>Cefotaxime</b>               | <b>199</b>    | <b>17</b>  | <b>101</b> | <b>67</b>  | <b>14</b> |
| J01XD01  | Metronidazole Parenteral        | 126           | 12         | 67         | 35         | 12        |
| J01CA01  | Ampicillin                      | 95            | 1          | 57         | 27         | 10        |
| J01CA04  | Amoxicillin                     | 82            |            | 41         | 31         | 10        |
| J01CR02  | Amoxicillin + Enzyme Inhibitor  | 79            | 7          | 62         | 7          | 3         |
| P01AB01  | Metronidazole oral              | 77            |            | 42         | 31         | 4         |
| J01EE01  | Cotrimoxazole                   | 49            |            | 32         | 14         | 3         |
| J01GB03  | Gentamycin                      | 43            | 2          | 24         | 13         | 4         |
| J01XA01  | Vancomycin Parenteral           | 31            | 7          | 15         | 9          |           |
| J01GB06  | Amikacin                        | 28            | 1          | 27         |            |           |
| J01DD04  | Ceftriaxone                     | 26            | 16         |            | 8          | 2         |
| J01FA01  | Erythromycin                    | 26            | 1          | 5          | 17         | 3         |
| J01AA02  | Doxycycline                     | 24            |            | 14         | 9          | 1         |
| J01DC02  | Cefuroxime                      | 17            | 2          | 10         | 4          | 1         |
| J01DH02  | Meropenem                       | 16            | 3          | 12         | 1          |           |
| J01MB02  | Nalidixic acid                  | 14            |            | 7          | 3          | 4         |
| J01CF02  | Cloxacillin                     | 13            |            | 8          | 2          | 3         |
| J01DB09  | Cefradine                       | 7             |            | 6          |            | 1         |
| J01CR05  | Piperacillin + Enzyme Inhibitor | 7             | 3          | 4          |            |           |
| J01DH51  | Imipenem combinations           | 5             | 5          |            |            |           |
| J01DD13  | Cefpodoxime                     | 4             | 2          | 1          | 1          |           |
| J01FF01  | Clindamycin                     | 4             |            | 2          | 2          |           |
| J01MA12  | Levofloxacin                    | 2             |            | 1          | 1          |           |
| J01FA10  | Azithromycin                    | 1             |            |            |            | 1         |
| J01CE01  | Benzylpenicillin                | 1             |            |            |            | 1         |
| J01DB04  | Cefazolin                       | 1             | 1          |            |            |           |
| J01DD02  | Ceftazidime                     | 1             |            | 1          |            |           |
| J01DB01  | Cephalexin                      | 1             | 1          |            |            |           |
| J01BA01  | Chloramphenicol                 | 1             |            | 1          |            |           |
| J01FA09  | Clarithromycin                  | 1             |            |            | 1          |           |
| J01GA01  | Streptomycin                    | 1             |            | 1          |            |           |
|          | <b>Total</b>                    | <b>982</b>    | <b>81</b>  | <b>541</b> | <b>283</b> | <b>77</b> |

# PRESCRIPTIONS ACROSS ANTIBIOTIC CLASSES AND HEALTH FACILITIES

| ABX Categories  | Specialist (%) | Tertiary (%) | District (%) | Primary (%) | Total (%) |
|-----------------|----------------|--------------|--------------|-------------|-----------|
| Cephalosporins  | 15.23          | <b>46.48</b> | 31.25        | 7.03        | 100.00    |
| Penicillins     | 2.96           | <b>62.22</b> | 24.81        | 10.00       | 100.00    |
| Macrolides      | 3.70           | 18.52        | <b>62.96</b> | 14.81       | 100.00    |
| Carbapenems     | <b>38.10</b>   | <b>57.14</b> | 4.76         | 0.00        | 100.00    |
| Aminoglycosides | 4.17           | <b>72.22</b> | 18.06        | 5.56        | 100.00    |
| Glycopeptides   | <b>22.58</b>   | <b>48.39</b> | <b>29.03</b> | 0.00        | 100.00    |


## INJECTABLE VS ORAL ANTIBIOTIC USE

| Ratio of                  | Specialist<br>N=57 | Tertiary<br>N=307 | District<br>N=280 | Primary<br>N=67 |
|---------------------------|--------------------|-------------------|-------------------|-----------------|
| Injectable antibiotic use | <b>1.37</b>        | <b>1.22</b>       | 0.60              | 0.67            |
| Oral antibiotic use       | 0.05               | 0.54              | 0.40              | 0.48            |

## DURATION OF SURGICAL PROPHYLAXIS

| Duration of Prophylaxis | Specialist (%)<br>N=27 | Tertiary (%)<br>N=58 | District (%)<br>N=31 | Primary (%)<br>N=2 |
|-------------------------|------------------------|----------------------|----------------------|--------------------|
| 1 Dose                  | 25.93                  | 0.00                 | 6.45                 | 0.00               |
| 1 Day                   | 7.41                   | 0.00                 | 3.23                 | 0.00               |
| > 1 Day                 | 66.67                  | <b>100.00</b>        | <b>90.32</b>         | 100.00             |

# ANTIBIOTIC USE IN SURGICAL PROPHYLAXIS (%) N=127



## CULTURE & SENSITIVITY TESTS

| <b>Culture &amp; Sensitivity Tests -</b> | <b>Specialist (%)<br/>N=57</b> | <b>Tertiary (%)<br/>N=307</b> | <b>District (%)<br/>N=280</b> | <b>Primary (%)<br/>N=67</b> |
|--|--------------------------------|-------------------------------|-------------------------------|-----------------------------|
| Ordered                                  | 29.82                          | 2.61                          | 3.57                          | 22.39                       |
| Reported                                 | 58.82                          | 50.00                         | 70.00                         | 26.67                       |
| Antibiotic therapy consolidated          | 100.00                         | 100.00                        | 0.00                          | 100.00                      |



# ASSESSMENT OF INSTITUTIONAL CAPACITY FOR PROMOTION OF ANTIMICROBIAL STEWARDSHIP



## A. INFRASTRUCTURE (N=10)

| #   | Indicator  | Score (%)                 |
|-----|--|---------------------------|
| 1.  | Availability of a formal ASP   | 20%                       |
| 2.  | ASP part of hospital's Organizational Structure                        | 40%                       |
| 3.  | An Appointed ASP team  | 20%                       |
| 4.  | ASP lead by a Physician  | 20%                       |
| 4a. | Who provides leadership? (Pharmacist)                                  | 10%                       |
| 5.  | Have an accessible Microbiologist                                      | 50%                       |
| 6.  | Have a responsible Pharmacist to ensure appropriate use of antibiotics | 50%                       |
| 7.  | Receive salary support for ASP activities                              | 0%                        |
| 8.  | Have IT support for ASP activities                                     | 40%                       |
| 9.  | Have a functioning Microbiology lab                                    | 100%                      |
| 10. | Number of culture tests done in last 3 months = 4261                   | Median 139 IQR 37.5-346.5 |

## A. INFRASTRUCTURE (N=10) CONT....

| #   | Indicator   | Score (%)          |
|-----|---|--------------------|
| 11. | Continuous supply of reagents for microbiology                      | 90%                |
| 12. | Availability of culture media in the past 90 days                   | 97.77% of lab days |
| 13. | Availability of antibiotic discs in the past 90 days                | 90%                |
| 14. | Availability of equipment for microbiology                          | 100%               |
| 15. | Availability of Botswana Antimicrobial Guidelines 2012 in the wards | 50%                |
| 16. | Have a functioning Infection Prevention & Control Committee         | 100%               |
| 17. | Have a functioning Drugs & Therapeutics Committee                   | 90%                |
| 18. | Availability of Botswana Essential Drugs List 2016 in the wards     | 40%                |

## B. POLICY & PRACTICE

| #   | Indicator  | Score (%) |
|-----|--|-----------|
| 19. | Have a facility specific treatment recommendation based on local CSTs                          | 20%       |
| 20. | Prescribing policy to document indication(s) on medical record                                 | 40%       |
| 21. | Routine practice for specified antimicrobials to be preauthorized by a Physician or Pharmacist | 60%       |
| 22. | Formal procedure to review appropriateness of antimicrobial after 48 hours                     | 0%        |
| 23. | Botswana Antimicrobial Guidelines 2012 used for empiric decision making                        | 40%       |
| 24. | Availability of current Antibiogram  | 20%       |
| 25. | Continuing education provided on local antimicrobial resistance pattern                        | 10%       |

## C. MONITORING & FEEDBACK

| #   | Indicator   | Score (%) |
|-----|---|-----------|
| 26. | Facility produced a cumulative antimicrobial susceptibility report                      | 20%       |
| 27. | Facility monitors if the indication for antimicrobial is captured in the medical record | 10%       |
| 28. | Facility audits or reviews choice of antimicrobials and duration                        | 20%       |
| 29. | The above audit results communicated directly with the prescribers                      | 20%       |
| 30. | Facility monitors DDDs or counts of antimicrobials per patient days                     | 0%        |
| 31. | Facility annual report focused on antimicrobial susceptibility                          | 0%        |
|     |   |           |

| <b>A. Infrastructure</b> |  | <b>Specialist<br/>(N=1)</b> | <b>Tertiary<br/>(N=1)</b> | <b>District<br/>(N=4)</b> | <b>Primary<br/>(N=4)</b> |
|--------------------------|--|-----------------------------|---------------------------|---------------------------|--------------------------|
| 1                        | Formal ASP   | 100                         | 0                         | 25                        | 0                        |
| 2                        | ASP part of Hospital Organogram  | 100                         | 0                         | 50                        | 25                       |
| 3                        | An appointed ASP Team  | 100                         | 0                         | 25                        | 25                       |
| 4                        | ASP lead by Physician  | ID Physician                | 0                         | 25                        | 0                        |
|                          | If not who?  |                             | Pharmacist                | None                      | None                     |
| 5                        | Microbiologist accessible  | 100                         | 100                       | 25                        | 25                       |
| 6                        | Pharmacist responsible for ASP   | 100                         | 100                       | 25                        | 25                       |
| 7                        | Salart Support for ASP   | 0                           | 0                         | 0                         | 0                        |
| 8                        | IT support for ASP   | 100                         | 100                       | 25                        | 25                       |
| 9                        | Functioning Microbiology Lab   | 100                         | 100                       | 100                       | 75                       |
| 10                       | Total number of culture tests conducted in the past 3 months?  | 2508                        | 739                       | 588                       | 396                      |
| 11                       | Continuous supply of reagents for culture media available in the last 3 months?                            | 100                         | 100                       | 75                        | 75                       |
| 12                       | Number of days in the past 3 months when cultures ingredients unavailable for preparing the culture media. | 0                           | 0                         | 20(1)                     | 5(1)                     |
| 13                       | Was there a continuous supply of Antibiotic Discs in the hospital in the last 3 months?                    | 100                         | 100                       | 100                       | 75                       |
| 14                       | Number of days in the past 3 months when Sensitivity Tests could not be performed?                         | 0                           | 0                         | 0                         | 0                        |
| 15                       | Number of days when Sensitivity Tests could not be performed due to a breakdown of equipment in the past   | 0                           | 0                         | 0                         | 0                        |
| 16                       | Botswana Antimicrobial Guidelines 2012 available in the ward?  | 0                           | 100                       | 50                        | 50                       |
| 17                       | Functioning Infection Prevention & Control Committee in the hospital?                                      | 100                         | 100                       | 100                       | 75                       |
| 18                       | Functioning Drugs and Therapeutics Committee in the hospital?  | 100                         | 0                         | 100                       | 75                       |
| 19                       | Was the current Botswana Essential Drug List June 2016 version available/accessible in the ward?           | 100                         | 100                       | 75                        | 75                       |

|                                   |   |     |     |    |    |
|-----------------------------------|---|-----|-----|----|----|
| 19                                | Was the current Botswana Essential Drug List June 2016 version available/accessible in the ward?  | 100 | 100 | 25 | 25 |
| <b>B. Policy and Practice</b>     |   |     |     |    |    |
| 20                                | Facility have specific treatment recommendations based on local antimicrobial susceptibility  | 0   | 100 | 50 | 0  |
| 21                                | Facility have a written policy that requires prescribers to document an indication in the medical record  | 100 | 0   | 50 | 0  |
| 22                                | Preauthorization for specified antimicrobial agents to be approved by a physician or pharmacist.  | 0   | 100 | 50 | 25 |
| 23                                | Procedure for a physician, pharmacist to do post prescription review after 48hrs?   | 0   | 0   | 0  | 0  |
| 24                                | Antimicrobial guidelines used at wards for empiric decision making?   | 0   | 0   | 75 | 25 |
| 25                                | Current antibiogram available in the hospital ( <b>with data from last 12 months</b> )?   | 100 | 100 | 0  | 0  |
| 26                                | Continuing education provided to prescribers on local Antimicrobial Resistance pattern  | 0   | 100 | 0  | 0  |
| <b>C. Monitoring and Feedback</b> |   |     |     |    |    |
| 27                                | Facility produced a cumulative antimicrobial susceptibility report in the past year?  | 100 | 100 | 0  | 0  |
| 28                                | Facility monitors if the indication is captured in the medical record for all antimicrobial prescriptions?  | 100 | 0   | 25 | 0  |
| 29                                | Facility audits or reviews surgical antimicrobial prophylaxis choice and duration?  | 100 | 0   | 25 | 0  |
| 30                                | Antimicrobial audits or reviews communicated directly with prescribers?   | 0   | 0   | 25 | 0  |
| 31                                | Facility monitors antimicrobial use by grams (Defined Daily Dose [DDD]) or counts (Days of Therapy [DOT]) of antimicrobial(s) by patients per days? | 0   |     | 0  | 0  |
| 32                                | ASP team produces an annual report focused on antimicrobial stewardship the past year?  | 0   | 0   | 0  | 0  |

# LIMITATIONS

- No on-site supervision and support for data collectors
- Committing time for data collection at the same work station was difficult though released from work due to staff shortages and the need to remain providing services.
- Confusion with several terminologies for diagnosis: Impression, Assessment, Query??? Rule out..... Etc.
- No standard template used for taking patient history; information may not be available, had to search volumes of notes. E.g. previous hospitalization, medication history etc...
- Some tests are not indicated for the admitted condition; therefore TB, Malaria, CD4 counts or HIV wasn't tested.
- Difficult to confirm a HAI as not recorded as the diagnosis and not elaborately defined in data collection tools.
- Field for “Antibiotic Stop date” was not provided
- Discrepant prescription orders: Electronic prescriptions when stopped; it wasn't stopped in drug administration sheets – the later used for the study as nurses use this to administer medications.
- Obtaining consent at some settings difficult due to participant bias (Moms of Paediatric and Neonatal)

## FURTHER ANALYSIS

- Calculate DDDs/Patient Days for comparison across populations
- Facility specific analysis of PPS data
- Assess compliance with antimicrobial guidelines and WHO guidelines.

# ACKNOWLEDGEMENTS

- Dr.V Sebako, Mr. Botsang John - Ministry of Health and Wellness Botswana
- Dr. C Tiroyakgosi - Botswana Essential Drugs Action Program
- Staff of Health Research and Development Unit MOHW Botswana
- University of Botswana
- Karolinska Institutet, Sweden
- Hospital managements and Research & Ethics Committees
- All in-service staff who extended their valuable service time for data collection. Mr. Emmanuel Molosiwa, Mr. Muthu Guhan Shanmugam, Dr. Joyce Kgatlwane, Mrs. Fatima Sinkala, Mrs. Mavis Gaolebe, Ms. Omphile Maakelo, Mrs. Joyce Masilo, Ms. Pearl Malepa, Ms. Stella Marumolo, Mr. Gbade Oladiran, Mr. O Tayopa, Mr. Evans Kagiso, Mr. Chris Makopa, Dr. Brighid Malone and the study team at Lenmed Bokamoso Private Hospital.



THANK YOU